Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2010 1
2012 1
2015 1
2016 1
2017 1
2018 2
2019 3
2020 6
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Beyond THC and Endocannabinoids.
Pacher P, Kogan NM, Mechoulam R. Pacher P, et al. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:637-659. doi: 10.1146/annurev-pharmtox-010818-021441. Epub 2019 Oct 3. Annu Rev Pharmacol Toxicol. 2020. PMID: 31580774 Review.
Numerous endocannabinoid-like compounds have been discovered. The Cannabis plant constituent cannabidiol (CBD) was found to exert beneficial effects in many preclinical disease models ranging from epilepsy, cardiovascular disease, inflammation, and autoimmuni …
Numerous endocannabinoid-like compounds have been discovered. The Cannabis plant constituent cannabidiol (CBD) was found to exert ben …
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.
Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, Laish I, Benjaminov F, Konikoff FM. Naftali T, et al. Dig Dis Sci. 2017 Jun;62(6):1615-1620. doi: 10.1007/s10620-017-4540-z. Epub 2017 Mar 27. Dig Dis Sci. 2017. PMID: 28349233 Clinical Trial.
Lacking any central effect, cannabidiol is an attractive option for treating inflammatory diseases. AIM: To assess the effects of cannabidiol on Crohn's disease in a randomized placebo-controlled trial. ...
Lacking any central effect, cannabidiol is an attractive option for treating inflammatory diseases. AIM: To assess the effects …
The nephrologist's guide to cannabis and cannabinoids.
Rein JL. Rein JL. Curr Opin Nephrol Hypertens. 2020 Mar;29(2):248-257. doi: 10.1097/MNH.0000000000000590. Curr Opin Nephrol Hypertens. 2020. PMID: 31972598 Free PMC article. Review.
RECENT FINDINGS: Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. ...SUMMARY: Patients and healthcare profes …
RECENT FINDINGS: Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-s …
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus.
Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Leino AD, et al. Am J Transplant. 2019 Oct;19(10):2944-2948. doi: 10.1111/ajt.15398. Epub 2019 May 21. Am J Transplant. 2019. PMID: 31012522 Free article.
Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. ...
Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with anticonvulsant properties, was approved by the U.S. ..
Cannabidiol.
[No authors listed] [No authors listed] 2019 Apr 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31644197 Free Books & Documents. Review.
Cannabidiol is an orally available cannabinoid that is used to treat patients with refractory epilepsy due to Lennox-Gastaut or Dravet syndrome. Cannabidiol is associated with frequent serum enzyme elevations during therapy particularly with higher doses but has not
Cannabidiol is an orally available cannabinoid that is used to treat patients with refractory epilepsy due to Lennox-Gastaut or Drave
In search of preventive strategies: novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues.
Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. Wang B, et al. Aging (Albany NY). 2020 Nov 22;12(22):22425-22444. doi: 10.18632/aging.202225. Epub 2020 Nov 22. Aging (Albany NY). 2020. PMID: 33221759 Free PMC article.
SARS-CoV-2 uses receptor-mediated entry into a human host via the angiotensin-converting enzyme 2 (ACE2), which is expressed in lung tissue as well as the oral and nasal mucosa, kidney, testes and gastrointestinal tract. The modulation of ACE2 levels in these gateway tissu …
SARS-CoV-2 uses receptor-mediated entry into a human host via the angiotensin-converting enzyme 2 (ACE2), which is expressed in lung tissue …
Regulation of Innate Lymphoid Cells in Acute Kidney Injury: Crosstalk between Cannabidiol and GILZ.
Baban B, Khodadadi H, Vaibhav K, Marchetti C, Riccardi C, Mozaffari MS. Baban B, et al. J Immunol Res. 2020 Feb 25;2020:6056373. doi: 10.1155/2020/6056373. eCollection 2020. J Immunol Res. 2020. PMID: 32185239 Free PMC article.
Thereafter, kidney cells were prepared for flow cytometry analyses. Sham kidneys treated with either cannabidiol or TAT-GILZ displayed similar frequencies of each subset of ILCs compared to DMSO or TAT, respectively. ...Indeed, cannabidiol treatment increased …
Thereafter, kidney cells were prepared for flow cytometry analyses. Sham kidneys treated with either cannabidiol or TAT-GILZ d …
Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury.
Soares RZ, Vuolo F, Dall'Igna DM, Michels M, Crippa JA, Hallak JE, Zuardi AW, Dal-Pizzol F. Soares RZ, et al. Rev Bras Ter Intensiva. 2015 Oct-Dec;27(4):383-9. doi: 10.5935/0103-507X.20150064. Rev Bras Ter Intensiva. 2015. PMID: 26761477 Free PMC article.
OBJECTIVE: This work aimed to investigate the effects of the administration of cannabidiol in a kidney ischemia/reperfusion animal model. METHODS: Kidney injury was induced by 45 minutes of renal ischemia followed by reperfusion. ...CONCLUSION: The cannabi
OBJECTIVE: This work aimed to investigate the effects of the administration of cannabidiol in a kidney ischemia/reperfusion an …
Impact of cannabidiol treatment on regulatory T-17 cells and neutrophil polarization in acute kidney injury.
Baban B, Hoda N, Malik A, Khodadadi H, Simmerman E, Vaibhav K, Mozaffari MS. Baban B, et al. Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1149-F1158. doi: 10.1152/ajprenal.00112.2018. Epub 2018 Jun 13. Am J Physiol Renal Physiol. 2018. PMID: 29897289 Free article.
Hallmark features of acute kidney injury (AKI) include mobilization of immune and inflammatory mechanisms culminating in tissue injury. ...The ability of cannabidiol to favor development of Treg17 cells was further established using functional mixed lymphocytic reac …
Hallmark features of acute kidney injury (AKI) include mobilization of immune and inflammatory mechanisms culminating in tissue injur …
Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs.
Jacobson KA, Reitman ML. Jacobson KA, et al. Cells. 2020 Apr 13;9(4):956. doi: 10.3390/cells9040956. Cells. 2020. PMID: 32295065 Free PMC article. Review.
Non-AR mechanisms include raising adenosine levels by inhibiting adenosine transport (e.g., ticagrelor, ethanol, and cannabidiol), affecting intracellular metabolic pathways (e.g., methotrexate, nicotinamide riboside, salicylate, and 5-aminoimidazole-4-carboxamide riboside …
Non-AR mechanisms include raising adenosine levels by inhibiting adenosine transport (e.g., ticagrelor, ethanol, and cannabidiol), af …
16 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page